ResMed (RMD)

Executive Summary

ResMed is a global leader in digital health and medical devices for respiratory care, with a dominant position in the sleep apnea market. The company's cloud-connected CPAP machines and masks, combined with its software analytics platform, create a sticky ecosystem that drives recurring revenue and improves patient outcomes. ResMed has consistently delivered strong financial performance, benefiting from increased awareness of sleep apnea and the shift toward home healthcare. Its recent expansion into COPD and other respiratory conditions, along with investments in digital therapeutics, positions it for sustained growth. However, competition from Philips (post-recall) and new entrants poses risks. Overall, ResMed's innovative product pipeline and data-driven care model provide a competitive moat, though valuation remains elevated. The company's focus on breathing health aligns with macro trends in aging populations and chronic disease management, supporting long-term demand. ResMed's growth strategy centers on penetrating international markets, launching next-generation devices, and expanding its digital health offerings. The company has a strong track record of regulatory approvals and reimbursement wins. Key near-term drivers include the rollout of the AirSense 11 platform in new geographies and the potential for FDA clearance of its digital COPD management solution. With a robust balance sheet and consistent free cash flow, ResMed is well-positioned to invest in R&D and pursue bolt-on acquisitions. While macroeconomic headwinds and supply chain constraints could impact short-term performance, the underlying demand for respiratory care remains resilient. The company's high switching costs and integrated ecosystem make it a core holding in the medtech space.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for digital COPD management platform80% success
• Q4 2026Launch of next-generation CPAP device with enhanced connectivity90% success
• Q2 2026Reimbursement expansion for sleep apnea therapy in key international markets70% success